Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

April’s top stories: BMS’s Opdivo trial, Merck and Pfizer’s lung cancer study

Bristol-Myers' Phase III lung cancer trial of Opdivo met its endpoint in a Phase III trial, Merck and Pfizer started an international Phase III lung cancer trial of avelumab, and AbbVie presented Phase IIIb Ruby-I data of hepatitis C treatment Viekirax+Exviera in patients with renal impairment. Drugdevelopment-technology.com wraps up key headlines from April.

Go Top